In this episode, we review the multi-center study led by Zhong and colleagues, which investigates the efficacy of combining bevacizumab with chemotherapy in relapsed ovarian cancer after prior PARP inhibitor maintenance therapy. The study found that patients receiving the combination achieved a median progression-free survival of 11 months compared to 9 months with chemotherapy alone, with notable benefits in platinum-resistant disease. While bevacizumab increased adverse events like neutropenia and hypertension, outcomes were generally favorable. Tune in to learn how this research could shape future treatment strategies for recurrent ovarian cancer.

Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis (https://doi.org/10.3802/jgo.2025.36.e36)